BEACON Study: Encorafenib, Binimetinib, and Cetuximab in BRAF-Mutant mCRC

Results from a phase 2 trial revealed serplulimab plus HLX04 elicited promising antitumor activity in patients with advanced hepatocellular carcinoma.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

At a longer follow-up, adagrasib with cetuximab maintained meaningful efficacy and elicited an ORR of 34%, results from the phase 1/2 KRYSTAL-1 showed.

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

The ALASCCA trial found that the risk of disease recurrence was reduced by 51% for patients with PIK3CA-mutated colorectal cancer who took aspirin for 3 years.

The BREAKWATER trial found that encorafenib and cetuximab with mFOLFOX6 chemotherapy generated an ORR of 60.9% in BRAF V600E–mutated metastatic colorectal cancer.